Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Paraneoplastic limbic encephalopathy.

E G Camara1, G J Chelune

  • 1Department of Psychiatry, Cleveland Clinic Foundation, Ohio 44106.

Brain, Behavior, and Immunity
|December 1, 1987
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

WMS-III performance in patients with temporal lobe epilepsy: group differences and individual classification.

Journal of the International Neuropsychological Society : JINS·2002
Same author

Comparability of the expanded WMS-III standardization protocol to the published WMS-III among right and left temporal lobectomy patients.

The Clinical neuropsychologist·2001
Same author

Temporal lobectomy in children: cognitive outcome.

Journal of neurosurgery·2000
Same author

Effects of anomalous language representation on neuropsychological performance in temporal lobe epilepsy.

Neurology·1999
Same author

Visual confrontation naming following left anterior temporal lobectomy: a comparison of surgical approaches.

Neuropsychology·1999
Same author

Does presurgical IQ predict seizure outcome after temporal lobectomy? Evidence from the Bozeman Epilepsy Consortium.

Epilepsia·1998
Same journal

Kynurenine pathway profiles as markers of ketamine response in treatment-resistant depression.

Brain, behavior, and immunity·2026
Same journal

Microglial brain-derived neurotrophic factor (BDNF) supports the behavioral and synaptogenic effects of ketamine.

Brain, behavior, and immunity·2026
Same journal

Hippocampal C5a-C5aR1 axis drives age-related memory decline via collapsing synaptic chloride homeostasis.

Brain, behavior, and immunity·2026
Same journal

Bifidobacterium bifidum TMC3115-RAW264.7 cell conditioned mediums promote the synaptic development of primary hippocampal neuron via activating IL-6/JAK2/STAT3 signaling pathway.

Brain, behavior, and immunity·2026
Same journal

T cells contribute to approaching positive but potentially risky stimuli through medial prefrontal cortex immune modulation.

Brain, behavior, and immunity·2026
Same journal

Insulin modulates mPFC gene expression and emotional behavior in a sex-specific manner following fetal growth restriction.

Brain, behavior, and immunity·2026
See all related articles

Paraneoplastic limbic encephalopathy (PLE) is a rare cancer complication causing significant cognitive changes, often preceding cancer diagnosis. This condition primarily affects memory, leading to an amnestic syndrome without widespread intellectual decline.

Area of Science:

  • Neurology
  • Oncology

Background:

  • Paraneoplastic limbic encephalopathy (PLE) is a nonmetastatic complication of carcinoma.
  • Neuropsychiatric symptoms can manifest years before cancer diagnosis.

Observation:

  • PLE presents with cognitive, affective, and behavioral changes.
  • Amnestic syndrome without generalized intellectual decline is a key feature.
  • Neuropsychological test results are crucial for diagnosis.

Findings:

  • This report details a case of PLE with comprehensive neuropsychological findings.
  • A review of similar literature cases highlights common features.
  • The study discusses potential causes and clinical implications of PLE.

Implications:

Related Experiment Videos

  • Early recognition of PLE's neuropsychiatric symptoms is vital for timely cancer detection.
  • Understanding PLE's mechanisms can improve patient outcomes.
  • This research contributes to the knowledge of autoimmune-mediated neurological disorders in cancer patients.